Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 8Prostatic Neoplasms 6Neoplasms, Plasma Cell 6Sarcoma 5Neoplasms 5Melanoma 4Liver Neoplasms 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Lymphoma, Follicular 3Leukemia 3Carcinoma, Renal Cell 3Brain Neoplasms 3Myelodysplastic Syndromes 2Lymphoma 2Kidney Neoplasms 2HIV Infections 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomatitis, Aphthous 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Endometrial Stromal 1Recurrent Uterine Corpus Sarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

Rituximab 14Bortezomib 9Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Filgrastim 5temsirolimus 4tanespimycin 4alvocidib 4Magnetic Resonance Spectroscopy 4Indium 4Cyclophosphamide 4ibritumomab tiuxetan 3Vorinostat 3Sirolimus 3Carboplatin 3sargramostim 2oblimersen 2ibrutinib 2belinostat 2Radiotherapy 2Pharmacogenomic Testing 2Methotrexate 2MK 2206 2Lenalidomide 2Interleukin-12 Subunit p35 2Interferon-alpha 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cyclosporine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Waldenstrom Macroglobulinemia × Thalidomide × Clear all
NCT00052416 2013-06-26

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡